Phase I/II trial of a low-emetic combination of S-1 plus docetaxel (DTX) for advanced non-small cell lung cancer (NSCLC).
Kenichiro Komiyama, Keisuke Eguchi(Keio University), Keigo Kobayashi(Osaka Gakuin University), Keiichiro Mori(Jikei University School of Medicine), Takashi Kasai, Shohei Minezaki, Mao Nakayama, E Hoshi, Shigeru Koyama, K Kikuchi, Yuka Uchida
Cited by 0
Related Papers
High Pressure NQR Measurement in CeCu<sub>2</sub>Si<sub>2</sub> up to Sudden Disappearance of Superconductivity
|Journal of the Physical Society of Japan|2008|78
Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
|Clinical Lung Cancer|2018|55
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations
|Proceedings of the National Academy of Sciences|2019|54
IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer
|Molecular Cancer Research|2020|54